Abstract
A population survey of 258 unrelated white British subjects showed a polymorphism for the 4-oxidation of debrisoquine. "Extensive metabolisers" (EM) and "poor metabolisers" (PM) are recognisable, 8.9% of the population being PM. Nine pedigrees ascertained through PM probands show that the PM phenotype is an autosomal Mendelian recessive character. The EM phenotype is dominant and the degree of dominance has been estimated at 30%. PM subjects are more prone to hypotension during debrisoquine therapy. The alleles controlling this polymorphism appear to control the oxidation of other drugs.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Idle J. R., Mahgoub A., Angelo M. M., Dring L. G., Lancaster R., Smith R. L. The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol. 1979 Mar;7(3):257–266. doi: 10.1111/j.1365-2125.1979.tb00930.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kitchen I., Tremblay J., André J., Dring L. G., Idle J. R., Smith R. L., Williams R. T. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica. 1979 Jul;9(7):397–404. doi: 10.3109/00498257909038744. [DOI] [PubMed] [Google Scholar]
- Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
- Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]